Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Red Light Holland Corp. C.TRIP

Alternate Symbol(s):  TRUFF

Red Light Holland Corp. is a Canada-based company. The Company is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, as well as a premium brand of psilocybin truffles in the legal recreational market within the Netherlands. Its subsidiaries include RLH Netherlands BV, RLH Farms BV, Red Light Holland (Subco 1) Inc., SR... see more

CSE:TRIP - Post Discussion

Red Light Holland Corp. > Linton departs MindMed
View:
Post by hfxpsy21 on Oct 01, 2021 9:06am

Linton departs MindMed

MINDMED ANNOUNCES APPOINTMENT OF ANDREAS KREBS AND CAROL VALLONE AS DIRECTORS AND TRANSITION OF BRUCE LINTON

The Mind Medicine Inc. board of directors has appointed Andreas Krebs and Carol Vallone as directors of the company, effective immediately. 

Mr. Krebs is an internationally experienced executive, entrepreneur and best-selling author ("The Illusion of Invincibility"). He heads the family-owned investment company Longfield Invest (Langenfeld/Germany), which focuses on growth companies in various industries as well as in the new economy. He has worked in seven countries, in Latin America, Asia and Canada and as president and executive board member of Wyeth Corp. in the United States. Mr. Krebs was chairman of the supervisory board and shareholder council of Merz Pharma, Frankfurt am Main, Germany, from 2010 to 2019, is currently a member of the supervisory board of the European eye clinic group Veonet (Nordic Capital Group) and holds other board positions across various sectors. Furthermore, he serves as chairman of the private non-governmental organization, Forderverein Girassol eV, which supports children and young people from socially difficult backgrounds in Sao Paulo, Brazil.

Ms. Vallone is a well-known business leader, former chief executive officer and corporate board director, with a strong record in launching, scaling and selling global companies. Currently, she serves as chair of the board of trustees at McLean Hospital, the No. 1 ranked freestanding psychiatric hospital and largest psychiatric affiliate of Harvard Medical School; serves on the board of trustees at MGH Institute of Health Professions; and serves on the finance committee at Mass General Brigham. Additionally, Ms. Vallone serves as a board member for the publicly traded Cresco Labs, and for a Bain Capital Double Impact portfolio company, Arosa. She is also an advisory director for the investment firm Berkshire Partners and an advisory board member of the health care-focused venture growth firm Longitude Capital. A serial entrepreneur, Ms. Vallone has served as founder and CEO of global e-learning companies, held manager positions in leading corporate technology companies and served on the boards of public financial services and e-commerce organizations. 

Mr. Krebs said: "Mental health issues directly or indirectly impact almost every one of us at some point in our lives. I'm thrilled at the opportunity to help MindMed find better solutions to this huge challenge in the coming years." 

Ms. Vallone said, "I feel privileged to support MindMed's esteemed team of scientists and business professionals in the pursuit of new medicines and therapies for those who suffer with mental illness." 

Effective Sept. 29, 2021, Bruce Linton stepped down from the company's board of directors in order to make room for the appointment of Ms. Vallone and Mr. Krebs. Mr. Linton said, "In a little over two years MindMed has gone from a topic that was frankly difficult to find support for, to attracting world-class talent and deep capacity capital." He added further, "I am delighted with the candidates joining and look forward to the world of change MindMed can achieve."

MindMed chair Perry Dellelce said: "We are extremely happy to welcome Carol and Andreas to the board. The depth of their collective experience with pharma, tech and health-focused organizations, combined with their extensive service on public company boards, will broaden and deepen the capabilities of the company's board of directors. As well, on behalf of the board of directors I would like to thank Bruce for his committed support and service on the company's board since the company's inception. I look forward to working with him on his next ventures." 

The appointments of Mr. Krebs and Ms. Vallone are subject to regulatory approval.

Comment by suomynona on Oct 01, 2021 2:39pm
Would a reasonable person not have pondered long ago that if it walks like a conflict of interest, and talks like a conflict of interest, that maybe... ?
Comment by SamRothstein on Oct 01, 2021 4:50pm
Would a reasonable person not have pondered long ago that if you post like a criminal, and talk like a criminal, that maybe you are in fact a criminal?  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities